adalimumab biosimilar (Polpharma Biologics)

Adalimumab biosimilar (Polpharma Biologics) is a recombinant human monoclonal antibody designed to mirror the reference product, Humira. It functions as a potent inhibitor of tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine that plays a central role in the pathogenesis of various autoimmune diseases. By binding specifically to soluble and transmembrane TNF-alpha, the antibody prevents the cytokine from interacting with its receptors (p55 and p75), thereby neutralizing its biological activity and suppressing the downstream inflammatory signaling pathways. Developed by Polpharma Biologics, this biosimilar is intended for the treatment of chronic inflammatory conditions such as rheumatoid arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis, offering a more accessible therapeutic option for patients requiring anti-TNF therapy.

Other names

adalimumab biosimilarPolpharma adalimumab